Matthaios Didagelos

Dr. Matthaios Didagelos

1st Cardiology, AHEPA University Hospital, Thessaloníki, Kentrikí Makedonía, Greece
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2008 in Surgical and Radiologic Anatomy
Verified
Journal Article
Closed access
PDF file
KNKonstantinos I. Natsis
Konstantinos I. Natsis
ITIoannis A. Tsitouridis
Ioannis A. Tsitouridis
Matthaios DidagelosMatthaios Didagelos
Matthaios Didagelos
AFAndis A. Fillipidis
Andis A. Fillipidis
KVKonstantinos G. Vlasis
Konstantinos G. Vlasis
PTProkopios D. Tsikaras
Prokopios D. Tsikaras

19 July 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
DCDamien Collison
Damien Collison
Matthaios DidagelosMatthaios Didagelos
Matthaios Didagelos
MAMuhammad Aetesam-Ur-Rahman
Muhammad Aetesam-Ur-Rahman
SCSamuel Copt
Samuel Copt
RMRobert McDade
Robert McDade
KOKeith G Oldroyd
Keith G Oldroyd
A fractional flow reserve (FFR) value ≥0.90 after percutaneous coronary intervention (PCI) is associated with a reduced risk of adverse cardiovascular events. TARGET-FFR is an investigator-initiated, single-centre, randomized controlled trial to determine the feasibility and efficacy of a post-PCI FFR-guided optimization strategy vs. standard coronary angiography in achieving final post-PCI FFR values ≥0.90. After angiographically guided PCI, patients were randomized 1:1 to receive a physiology-guided incremental optimization strategy (PIOS) or a blinded coronary physiology assessment (control group). The primary outcome was the proportion of patients with a final post-PCI FFR ≥0.90. Final FFR ≤0.80 was a prioritized secondary outcome. A total of 260 patients were randomized (131 to PIOS, 129 to control) and 68.1% of patients had an initial post-PCI FFR <0.90. In the PIOS group, 30.5% underwent further intervention (stent post-dilation and/or additional stenting). There was no significant difference in the primary endpoint of the proportion of patients with final post-PCI FFR ≥0.90 between groups (PIOS minus control 10%, 95% confidence interval −1.84 to 21.91, P = 0.099). The proportion of patients with a final FFR ≤0.80 was significantly reduced when compared with the angiography-guided control group (−11.2%, 95% confidence interval −21.87 to −0.35], P = 0.045). Over two-thirds of patients had a physiologically suboptimal result after angiography-guided PCI. An FFR-guided optimization strategy did not significantly increase the proportion of patients with a final FFR ≥0.90, but did reduce the proportion of patients with a final FFR ≤0.80. Findings of initial post-percutaneous coronary intervention fractional flow reserve and pullback assessments. (A) Post-percutaneous coronary intervention fractional flow reserve results following standard-of-care stenting [*238/260 (92%) with core lab-adjudicated post-percutaneous coronary intervention fractional flow reserve results available for analysis]. (B) Summary findings of 259 initial post-percutaneous coronary intervention fractional flow reserve pullback assessments (pre-randomization) demonstrating the patterns of residual disease in the study vessels. Protocol-defined targets for additional optimization measure in red bars. Multiple findings may have co-existed within individual vessels. Focal lesion defined as an abrupt pressure drop ≥0.05 fractional flow reserve units on pullback. (C) Primary endpoint—Proportion of patients with final post-percutaneous coronary intervention fractional flow reserve value ≥0.90. (D) Secondary endpoint—Proportion of patients with final post-percutaneous coronary intervention fractional flow reserve ≤0.80. Diffuse Distal, diffuse pressure gradient distal to stented segment; Diffuse Proximal, diffuse pressure gradient proximal to stented segment; Focal Distal, focal pressure drop distal to stented segment; Focal Proximal, Focal pressure drop proximal to stented segment; FFR, fractional flow reserve; HTG, hyperaemic trans-stent gradient; PCI, percutaneous coronary intervention.

20 December 2016 in Surgical and Radiologic Anatomy
Verified
Journal Article
Closed access
PDF file
KNKonstantinos Natsis
Konstantinos Natsis
Matthaios DidagelosMatthaios Didagelos
Matthaios Didagelos
AGAnna Gkiouliava
Anna Gkiouliava
NLNikolaos Lazaridis
Nikolaos Lazaridis
VVVasilios Vyzas
Vasilios Vyzas
Maria PiagkouMaria Piagkou
Maria Piagkou

18 May 2020 in Journal of Human Hypertension
Verified
Journal Article
Closed access
PDF file
VKVasiliki Katsi
Vasiliki Katsi
MMMaria Marketou
Maria Marketou
SMSpyridon Maragkoudakis
Spyridon Maragkoudakis
Matthaios DidagelosMatthaios Didagelos
Matthaios Didagelos
GCGeorgios Charalambous
Georgios Charalambous
DTDimitrios Tousoulis
Dimitrios Tousoulis

22 June 2020 in Angiology
Verified
Journal Article
Closed access
PDF file
GKGeorge Kassimis
George Kassimis
Matthaios DidagelosMatthaios Didagelos
Matthaios Didagelos
GMGiovanni Luigi De Maria
Giovanni Luigi De Maria
NKNestoras Kontogiannis
Nestoras Kontogiannis
GKGrigoris V. Karamasis
Grigoris V. Karamasis
ABAdrian P. Banning
Adrian P. Banning
Vascular calcification is a highly prevalent pathophenotype that is associated with aging, atherosclerotic cardiovascular disease, diabetes mellitus, and chronic kidney disease. When present, it portends a worse clinical outcome and predicts major adverse cardiovascular events. Heavily calcified coronary and peripheral artery lesions are difficult to dilate appropriately with conventional balloons during percutaneous intervention, and the use of several adjunctive strategies of plaque modification has been suggested. Intravascular lithotripsy (IVL) offers a novel option for lesion preparation of severely calcified plaques in coronary and peripheral vessels. It is unique among all technologies in its ability to modify calcium circumferentially and transmurally, thus modifying transmural conduit compliance. In this article, we summarize the currently available evidence on this technology, and we highlight its best clinical application through appropriate patient and lesion selection, with the main objective of optimizing stent delivery and implantation, and subsequent improved short- and long-term outcomes. We believe that the IVL balloon will transform the market, as it is easy to use, with predictable results. However, cost-effectiveness of such advanced technology will need to be considered.

1 April 2023 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
DCDamien Collison
Damien Collison
SCSamuel Copt
Samuel Copt
TMTakuya Mizukami
Takuya Mizukami
CCCarlos Collet
Carlos Collet
RMRuth McLaren
Ruth McLaren
KOKeith G. Oldroyd
Keith G. Oldroyd
Background: Twenty percent to 40% of patients are affected by angina after percutaneous coronary intervention (PCI), which is associated with anxiety, depression, impaired physical function, and reduced quality of life. Understanding patient and procedural factors associated with post-PCI angina may inform alternative approaches to treatment. Methods: Two hundred thirty patients undergoing PCI completed the Seattle Angina Questionnaire (SAQ-7) and European quality of life–5 dimension–5 level (EQ-5D-5L) questionnaires at baseline and 3 months post-PCI. Patients received blinded intracoronary physiology assessments before and after stenting. A post hoc analysis was performed to compare clinical and procedural characteristics among patients with and without post-PCI angina (defined by follow-up SAQ-angina frequency score <100). Results: Eighty-eight of 230 patients (38.3%) reported angina 3 months post-PCI and had a higher incidence of active smoking, atrial fibrillation, and history of previous myocardial infarction or PCI. Compared with patients with no angina at follow-up, they had lower baseline SAQ summary scores (69.48±24.12 versus 50.20±22.59, P <0.001) and EQ-5D-5L health index scores (0.84±0.15 versus 0.69±0.22, P <0.001). Pre-PCI fractional flow reserve (FFR) was lower among patients who had no post-PCI angina (0.56±0.15 versus 0.62±0.13, P =0.003). Percentage change in FFR after PCI had a moderate correlation with angina frequency score at follow-up ( r =0.36, P <0.0001). Patients with post-PCI angina had less improvement in FFR (43.1±33.5% versus 67.0±50.7%, P <0.001). There were no between-group differences in post-PCI FFR, coronary flow reserve, or corrected index of microcirculatory resistance. Patients with post-PCI angina had lower SAQ-summary scores (64.01±22 versus 95.16±8.72, P ≤0.001) and EQ-5D-5L index scores (0.69±0.26 versus 0.91±0.17, P ≤0.001) at follow-up. Conclusions: Larger improvements in FFR following PCI were associated with less angina and better quality of life at follow-up. In patients with stable symptoms, intracoronary physiology assessment can inform expectations of angina relief and quality of life improvement after stenting and thereby help to determine the appropriateness of PCI. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03259815.